Overview

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Status:
Recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

University of Utah

Collaborators:

Acrotech Biopharma
Novartis

Treatments:

Belinostat